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MicroRNAs regulation  
of mitochondria-rich cells
Flynt et al., J Cell Biol 2009; 185: 115–127; doi:10.1083/jcb.200807026
A well-characterized cell type called the mitochondria-rich 
cell, or ionocyte, is present in many ion-transporting epithelia, 
and it is capable of transporting ions against a concentration 
gradient. It is found in a variety of organs, including the kid-
neys of all amniotes, the urinary system and skin of amphibia, 
and the gills and skin of teleost fish. The main characteristics 
of these cells are a high abundance of mitochondria and a 
large number of apical microvilli that highly express ATPases, 
mainly Na+/K+-ATPases and V-type H+-ATPases. The zebrafish 
has emerged as a useful genetic model for the study of verte-
brate kidney development. In these fish, mitochondria-rich 
cells play essential roles in the transepithelial transportation 
of ions and water, and in the acid–base balance in the skin 
of the fish embryo before their branchial counterparts are 
fully functional. MicroRNAs (miRNAs) are a class of small 
(approximately 22-nucleotide) noncoding RNAs that negatively 
regulate specific mRNAs and thus enable precise control of 
gene expression. Higher eukaryotic genomes encode anywhere 
from hundreds to thousands of miRNAs; identifying the exact 
genes regulated by specific miRNAs remains a difficult prob-
lem. The sequences of many miRNAs are conserved, showing 
similar expression patterns, genomic organization, and copy 
numbers. Thus, Flynt et al. postulate that genetically tractable 
organisms such as zebrafish could yield insight into the role 
of miRNAs in humans and their potential role in physiology 
and disease. The authors focused on the miR-8 family, which is 
expressed in several organs containing mitochondria-rich cells. 
They found that the miR-8 family is expressed in ionocytes of 
the skin of zebrafish embryos, and that knockdown of miR-8 
did not affect zebrafish development. However, knockdown of 
miR-8 impaired osmotic regulation of the embryos as well as 
inhibiting sodium (Na) entry into ionocytes by inhibition of 
Na+/hydrogen (H)+ exchangers (Figure). As shown, accumula-
tion of Na+ in zebrafish embryos depended on the pH of the 
culture water, with embryos raised at low pH exhibiting the 
greatest accumulation. This is because Na+ accumulation was 
dependent on the function of Na+/H+ exchangers (NHEs) and, 
thus, linked to H+ efflux. The authors also found that the miR-8 
family enabled precise control of ion transport by modulat-
ing the expression of Nherf1, which is a regulator of apical 
trafficking of transmembrane ion transporters. As ionocytes 
functionally mimic intercalated cells in the mammalian distal 
nephron and collecting duct, these results provide important 
insights into the regulation of critical functions of the distal 
nephron by miRNA.
Juan Oliver
Lowering blood pressure improves 
risk of cardiovascular events and 
mortality in patients on dialysis
Heerspink et al., Lancet 2009; 373: 1009–1015; doi:10.1016/
S0140-6736(09)60212-9
Patients with end-stage renal disease maintained on dialysis 
have a very high risk of cardiovascular mortality and 
morbidity as compared with those patients not receiving 
dialysis. Although a few trials have shown that lowering 
blood pressure benefits the cardiovascular health of the 
general population, the efficacy and tolerability of reducing 
blood pressure in patients on dialysis remain uncertain. 
Now, Heerspink et al. present a systematic review and meta-
analysis that assesses the effect of lowering blood pres-
sure in patients on dialysis. The authors searched Medline, 
Embase, and the Cochrane Library database for randomized, 
controlled trials of blood pressure lowering in patients on 
dialysis that reported cardiovascular outcomes between 
1950 and November 2008. They then identified eight trials 
that included data for 1679 patients with 495 cardiovascular 
events. Weighted mean systolic blood pressure in this group 
was 4.5 mm Hg lower and diastolic blood pressure 2.3 mm Hg 
lower in actively treated patients than in controls. Treatment 
for lower blood pressure was associated with lower risks of 
cardiovascular events, all-cause mortality, and cardiovascular 
mortality than were seen in controls. The authors draw the 
important conclusion that treatment with blood pressure-
lowering agents should be considered routinely for patients 
undergoing dialysis to help reduce their high rates of cardio-
vascular morbidity and mortality.
Marc De Broe
Loss of miR-8 miRNAs blocks Na+ accumulation in ionocytes by 
inhibition of Na+/H+ exchangers. (a–c) Live wild-type zebrafish 
embryos were incubated with Sodium green (which emits 
fluorescence in correlation with increasing Na+ concentration; green) 
and MitoTracker red (marker for the ionocytes; red) at pH 5.0, 7.0,  
or 10.0. Na+ accumulation is indicated by green-stained cells.  
(d–f) Live embryos with knockdown of miR-8. 
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Association of kallikrein genes 
with lupus and anti–glomerular 
basement membrane nephritis
Liu et al., J Clin Invest 2009; 119: 911–923; doi:10.1172/JCI36728
The experimental anti−glomerular basement membrane (GBM) 
antibody-induced glomerulonephritis (AIGN) model, wherein 
the transfer of anti-GBM antibodies elicits glomerulonephritis, 
is a useful model to study the pathogenesis of immune-mediated 
nephritis in lupus and Goodpasture’s disease. Although the spe-
cificities of the inciting antibodies likely differ in experimen-
tal AIGN and spontaneous lupus nephritis, the downstream 
pathogenic cascades that lead to disease appear to be similar. 
Remarkably, in more than 20 inbred mouse strains challenged 
with anti-GBM antibodies, severe renal disease was noted in 
only five strains, including DBA/1, NZW, and 129/SvJ. In addi-
tion, the latter two strains are known to develop spontaneous 
lupus nephritis. Xie et al. previously reported that the strain dif-
ferences in AIGN susceptibility cannot simply be attributed to 
differences in systemic immune response (to the administered 
rabbit anti-mouse GBM antibodies) or to differences in Th1 
skewing.1,2 Thus, whether renal-intrinsic differences may con-
tribute to the observed strain differences in AIGN susceptibility 
remains unknown. Accordingly, Liu et al. undertook a microar-
ray-based transcriptomic analysis of the renal cortex from three 
AIGN-sensitive strains and two control strains, after anti-GBM 
challenge. Surprisingly, they found that a significant fraction of 
the differentially expressed genes that distinguish the nephritis-
sensitive strains from the control strains belonged to the kal-
likrein (Klk) gene family. Mouse strains that upregulated renal 
and urinary kallikreins exhibited less evidence of disease, and 
antagonizing the kallikrein pathway augmented disease, whereas 
agonists dampened the severity of anti-GBM antibody-induced 
nephritis (Figure). In addition, nephritis-sensitive mouse strains 
had kallikrein haplotypes that were distinct from those of control 
strains, including several regulatory polymorphisms, some of 
which were associated with functional consequences. Indeed, 
increased susceptibility to anti-GBM antibody-induced nephritis 
and spontaneous lupus nephritis was achieved by the breeding 
of mice with a genetic interval harboring the kallikrein genes 
onto a disease-resistant background. Finally, the authors found 
that both human systemic lupus erythematosus and spontaneous 
lupus nephritis were associated with kallikrein genes, particu-
larly KLK1 and the KLK3 promoter, when DNA single-nucleotide 
polymorphisms from independent cohorts of lupus patients and 
controls were compared. Kallikreins constitute a multigene family 
of serine esterases with a wide spectrum of biological functions, 
including regulation of inflammation, apoptosis, redox balance, 
and fibrosis within the kidneys, as well as local blood pressure. 
In the aggregate, these studies suggest that kallikreins are pro-
tective disease-associated genes in anti-GBM antibody-induced 
nephritis and lupus.
Juan Oliver
1Arthritis Rheum 2003; 48: 1080–1092. 2J Immunol 2004; 172: 5047–5055.
Statins and cardiovascular events 
in ESRD patients  
undergoing hemodialysis
Fellström et al., N Engl J Med 2009; 360: 1395–1407; doi:10.1056/ 
NEJMoa0810177
The results of Die Deutsche Diabetes Dialyse Studie (the 4D 
study)1 suggest that statins may not reduce cardiovascular disease 
in end-stage renal disease (ESRD) patients with type 2 diabetes 
mellitus more than in persons with normal kidney function. Dis-
cussion following this trial asked whether the dose of atorvastatin 
was sufficiently high and whether the volunteer subjects recruited 
had a lower event rate than expected in order to find reasons 
for the relatively neutral results. The AURORA trial (A Study to 
Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodi-
alysis: An Assessment of Survival and Cardiovascular Events), a 
multicenter, double-blind study, randomized 2776 ESRD patients 
undergoing dialysis to receive rosuvastatin, 10 mg daily, or pla-
cebo. Unlike the 4D trial, which enrolled only patients with ESRD 
and type 2 diabetes mellitus, AURORA did not limit enrollment 
to those with diabetes. The combined primary end point was a 
composite of cardiovascular death, nonfatal myocardial infarc-
tion, or nonfatal stroke. No differences were found in the rates of 
the primary event of mortality between treatment arms.
While these trials differ with respect to the etiology of the 
subjects’ kidney disease, the results are similar. The potential for 
a type II statistical error that was discussed after the 4D study 
results now appears remote. The AURORA trial confirms the 
failure of statins to prevent cardiovascular-related events in 
ESRD patients. Clearly, the burden of cardiovascular disease is 
established and extensive in patients with ESRD. Determining 
whether this increased burden requires more treatment with 
standard therapies or other strategies used among patients with 
normal kidney function is our next challenge.
Lynda Szczech
1N Engl J Med 2005; 353: 238–248.
Effect of bradykinin administration on severity of antibody-induced 
glomerulonephritis. Bradykinin given to 129/SvJ mice by osmotic pumps 
ameliorated proteinuria after anti–glomerular basement membrane 
administration, in comparison with mice treated with vehicle placebo.
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